CDC Issues Recs on Diagnosis, Management of Pediatric mTBI
THURSDAY, Sept. 6, 2018 -- The U.S. Centers for Disease Control and Prevention has established an evidence-based guideline for diagnosis and management of pediatric mild traumatic brain injury (mTBI). The guideline was published online Sept. 4 in JAMA Pediatrics.
Angela Lumba-Brown, M.D., from the Stanford University School of Medicine in California, and colleagues conducted a systematic review of the pediatric mTBI literature in order to develop an evidence-based guideline with clinical recommendations for diagnosis and management. Six clinical questions were selected on diagnosis, prognosis, and management or treatment of pediatric mTBI.
Based on the evidence, the researchers developed 19 sets of recommendations on the diagnosis, prognosis, and management/treatment of pediatric mTBI; based on confidence in the evidence, these were assigned a level of obligation. Imaging, symptom scales, cognitive testing, and standardized assessment for diagnosis were addressed in the recommendations, as were assessment of history and risk factors, monitoring, and counseling for prognosis. In terms of management/treatment, patient/family education, rest, support, return to school, and symptom management were addressed.
"This guideline identifies the best practices for mTBI based on the current evidence; updates should be made as the body of evidence grows," the authors write. "CDC has created user-friendly guideline implementation materials that are concise and actionable. Evaluation of the guideline and implementation materials is crucial in understanding the influence of the recommendations."
Several authors disclosed financial ties to the pharmaceutical, medical device, and sports industries.
© 2020 HealthDay. All rights reserved.
Posted: September 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.